$AbCellera Biologics(ABCL)$ $Moderna, Inc.(MRNA)$ $SELLAS Life Sciences Group Inc.(SLS)$ $Eli Lilly(LLY)$ $Johnson & Johnson(JNJ)$ ABCL has put out its November investor conference participation schedule. To me this looks like more than just a notice for institutional investors, it seems tied to the next clinical phase for ABCL635. The key question is whether the 12-week data we've been waiting for comes out with the earnings release, or gets a separate announcement later.
Upcoming schedule:
October 22 - Poster presentation on the ABCL635 Phase 1/2 trial at the TMS 2026 Conference
November 9 - Q3 2026 earnings release and conference call
November 11 - Stifel Healthcare Conference
November 16 - Jefferies Global Healthcare Conference
Q4 2026 - ABCL575 Phase 1 clinical results presentation scheduled
By the end of 2026 - expecting 12-week data for ABCL635 and updates on subsequent clinical information.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
